We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Abbott Backs Down In Kaletra Pricing Fight

Law360 (April 11, 2007, 12:00 AM EDT) -- Abbott Laboratories said Tuesday it will slash the price of Kaletra by more than half in a slew of developing nations, following months of international pressure over the pharmaceutical giant's drug pricing policies in Thailand, which recently broke a patent on the HIV/AIDS treatment.

The drug maker said it will offer Kaletra, its “second-line” treatment for HIV/AIDS, to the governments of more than 40 low and low-middle income countries and nongovernmental organizations at $1,000 per patient per year.

That price tag is lower than any generic...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.